Business Context and Reporting Period
Company: LeMaitre Vascular, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 2010
Business Overview: LeMaitre Vascular develops, manufactures, and markets medical devices and implants for vascular surgery. Principal product lines include thoracic and abdominal stent grafts, anastomotic clips, vascular grafts, and balloon catheters. The company operates in a single segment with significant sales in the United States, Europe, and Japan.
Key Financial Metrics
| Metric | Q1 2010 | Q1 2009 |
|---|---|---|
| Net Sales | $13,815,000 | $11,348,000 |
| Gross Profit | $10,318,000 | $8,266,000 |
| Gross Margin | 74.7% | 72.8% |
| Operating Income | $1,270,000 | ($1,566,000) |
| Net Income | $1,021,000 | ($1,881,000) |
| Diluted EPS | $0.06 | ($0.12) |
| Cash and Cash Equivalents | $23,662,000 | $14,093,000 |
| Long-Term Debt | $149,000 | $188,000 |
| Operating Cash Flow | $819,000 | ($2,306,000) |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 22% year-over-year. Organic growth (excluding currency and acquisitions) was 18%, driven by higher average selling prices and increased volume in Vascular category products (Valvulotomes, AlboGraft, XenoSure).
- Profitability Turnaround: The company returned to profitability with $1.0 million in net income, compared to a $1.9 million net loss in Q1 2009. This improvement was significantly aided by the absence of a $1.8 million restructuring charge and a $0.1 million impairment charge recorded in the prior year.
- Expense Management: Total operating expenses decreased 8% to $9.0 million. While Sales & Marketing and R&D expenses increased due to sales growth and clinical trial enrollment, these were offset by the elimination of prior-year restructuring costs.
- Cash Position: Cash and cash equivalents increased by $9.6 million to $23.7 million, supported by positive operating cash flow of $0.8 million.
Outlook, Risks, and Management Commentary
- Foreign Currency: Approximately 42% of sales are denominated in foreign currencies. A weaker U.S. dollar contributed a 3% positive impact to sales growth in Q1 2010. Management notes that currency fluctuations remain a risk to future results.
- R&D and Clinical Trials: R&D expenses increased 17% due to higher product development and clinical trial costs. The company enrolled 55 patients in the UNITE clinical trial as of March 31, 2010, and anticipates R&D expenses will continue to rise as enrollment progresses.
- Liquidity: The company maintains a $10.0 million revolving credit facility with no outstanding balance. Management believes existing cash and marketable securities ($24.1 million total) are sufficient to meet requirements for the next 12 months.
- Stock Repurchase: The company repurchased 66,072 shares for $0.3 million under its $2.0 million program, with $1.2 million remaining available.
- Product Discontinuation: The company discontinued the aSpire Stent in March 2010, resulting in inventory write-downs that partially offset gross margin improvements.
Investor Verification Checklist
- Organic Growth Sustainability: Verify if the 18% organic sales growth is sustainable without the one-time benefits of the AlboGraft distribution termination transition.
- Currency Exposure: Monitor the impact of foreign exchange rate fluctuations on future margins, given that 42% of sales are in foreign currencies.
- R&D Burn Rate: Track the pace of the UNITE clinical trial enrollment and its correlation to rising R&D expenses.
- Inventory Management: Review future inventory levels and potential write-downs related to the discontinued aSpire Stent line.
- Tax Position: Note the valuation allowance against deferred tax assets; future profitability could trigger a reversal of this allowance, impacting the effective tax rate.